Olympus opts for Munich site for life sciences R&D (research and development) centre:
This article was originally published in Clinica
Japanese camera and medical products developer Olympus has opted to locate its new life science research and development centre in Munich, Germany. Tokyo-based Olympus will invest some Euro15m ($21m) in the project, which will be opened officially in October. By 2009, it will be employing a staff of 450, who will be involved in production as well as R&D in the fields of molecular diagnostics, laboratory automation and digital processing in microscopy. Olympus' regional HQ, Olympus Europa Holding, is located in Hamburg. The proximity of the University Hospital Grosshadern to the new Bavarian site was an advantage, said Olympus regional executive managing director Dr Helmut Kohler. The group will be working in close co-operation with the hospital.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.